NCH93人类间变性脑膜瘤（WHO III 级）细胞株-BioVector NTCC 典型培养物保藏中心

Key Characteristics and Research Applications

• Origin: Derived from a human anaplastic (WHO Grade III) meningioma located in the left parieto-occipital region of the brain.

• Growth Properties: Exhibits mixed growth properties (both adherent and suspension) and has a biosafety level of 2.

• Genetics: Targeted panel sequencing revealed key mutations, including a deleterious frameshift deletion in the NF2 gene and pathogenic missense mutations in the ALK and PTCH1 genes.

• Tumorigenicity: NCH93 cells are highly tumorigenic and form fast-growing tumors when injected into immunodeficient mice, making them a valuable in vivo model for aggressive meningioma research.

• Research Focus: Due to a lack of robust human anaplastic meningioma models, NCH93 has been instrumental in research aimed at identifying new prognostic markers and therapeutic targets. Studies have used this cell line to:

  • Identify KIF11 as a potential novel therapeutic target, as its knockdown significantly inhibited tumor cell proliferation.

  • Screen FDA-approved drugs and drug combinations, identifying promising agents like ponatinib, bortezomib, and carfilzomib for treatment.

  • Establish and validate ANXA3 as a potential target in meningioma.

  
  

• 起源： 来自人类脑膜瘤组织，具有高度恶性（III 级）特征。

• 生长特性： 具有混合生长特性（贴壁生长和悬浮生长），生物安全等级为2级。

• 遗传学特征： 基因测序显示存在关键基因突变，包括NF2基因的有害移码缺失以及ALK和PTCH1基因的致病性错义突变。

• 致瘤性： NCH93细胞具有高度致瘤性。当注射到免疫缺陷小鼠体内时，会迅速形成肿瘤，是侵袭性脑膜瘤体内研究的重要模型。

• 研究价值： 由于缺乏可靠的人类间变性脑膜瘤模型，NCH93细胞系在寻找新的预后标志物和治疗靶点方面发挥了关键作用。相关研究包括：

  • 确定KIF11（驱动蛋白家族成员）作为潜在的新治疗靶点，敲低KIF11可显著抑制肿瘤细胞增殖。

  • 筛选FDA批准的药物，发现普纳替尼（ponatinib）、硼替佐米（bortezomib）和卡非佐米（carfilzomib）等药物对治疗侵袭性脑膜瘤有前景。

  • 验证ANXA3作为脑膜瘤潜在靶点的作用

  
  

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: biovector@163.com

http://www.biovector.net